MedTrace Logo

CSF Protein Markers as Prognostic Indicators of the Response to CSF Shunt in Normotensive Hydrocephalus

NCT05915000 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2026-04-22

No results posted yet for this study

Summary

In all published series of adult chronic hydrocephalus, there is a percentage between twenty and twenty-five percent of patients who present poor results after implantation of a cerebrospinal fluid shunt,1-11 usually ventriculoperitoneal. The lumboperitoneal shunt is also used but much more rarely.

The diagnosis of this pathology is based on the clinical picture, neuroimaging studies (Evans index and corpus callosum angle), cerebrospinal fluid dynamics tests (Katzman test), and invasive intracranial pressure measurements. Despite all this diagnostic arsenal, there is a high percentage of patients (mentioned above) in which treatment by diversion of cerebrospinal fluid does not offer the expected results. Traditionally, this has been attributed to chronic adult hydrocephalus being associated with other types of dementia. This may be the case in some patients, and it would be important to predict which patients will not improve or who will improve poorly in the case of insertion of a cerebrospinal fluid shunt.

Conditions

  • Beta-amiloid and Phospho-tau Proteins in CSF
  • Ventricular Size After CSF Shunt
  • Cognitive Impairment and CSF Shunt
  • Motor Impairment Evolution After CSF Shunt

Interventions

DIAGNOSTIC_TEST

Lumbar CSF protein marker determination

The cerebrospinal fluid levels of the Aβ1-42 amyloid, h-tau and phospho-tau proteins will be assessed. The response of patients to the possible implantation of a ventricular peritoneal shunt will be assessed through neuropsychological, gait and ventricular size studies assessed through cerebral magnetic resonance studies.

Sponsors & Collaborators

  • University of Valencia

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-13
Primary Completion
2029-03-17
Completion
2029-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05915000 on ClinicalTrials.gov